vs
Side-by-side financial comparison of Carlyle Group Inc. (CG) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Carlyle Group Inc. is the larger business by last-quarter revenue ($1.9B vs $1.1B, roughly 1.7× PERRIGO Co plc). Carlyle Group Inc. runs the higher net margin — 18.8% vs -127.8%, a 146.6% gap on every dollar of revenue. On growth, Carlyle Group Inc. posted the faster year-over-year revenue change (84.1% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-1.2B). Over the past eight quarters, Carlyle Group Inc.'s revenue compounded faster (66.2% CAGR vs 1.3%).
The Carlyle Group Inc. is an American multinational company with operations in private equity, alternative asset management and financial services. As of 2023, the company had $426 billion of assets under management.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
CG vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.1B |
| Net Profit | $358.1M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 24.3% | -116.0% |
| Net Margin | 18.8% | -127.8% |
| Revenue YoY | 84.1% | -2.5% |
| Net Profit YoY | 69.8% | -3093.9% |
| EPS (diluted) | $0.96 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | $1.1B | ||
| Q3 25 | $332.7M | $1.0B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $973.1M | $1.0B | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $2.6B | $1.1B | ||
| Q2 24 | $1.1B | $1.1B | ||
| Q1 24 | $688.4M | $1.1B |
| Q4 25 | $358.1M | $-1.4B | ||
| Q3 25 | $900.0K | $7.5M | ||
| Q2 25 | $319.7M | $-8.4M | ||
| Q1 25 | $130.0M | $-6.4M | ||
| Q4 24 | $210.9M | $-44.4M | ||
| Q3 24 | $595.7M | $-21.0M | ||
| Q2 24 | $148.2M | $-108.4M | ||
| Q1 24 | $65.6M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 24.3% | -116.0% | ||
| Q3 25 | 25.8% | 7.0% | ||
| Q2 25 | 28.0% | 4.3% | ||
| Q1 25 | 17.6% | 4.5% | ||
| Q4 24 | 25.7% | 10.0% | ||
| Q3 24 | 29.9% | 7.4% | ||
| Q2 24 | 20.5% | -2.5% | ||
| Q1 24 | 17.5% | -5.1% |
| Q4 25 | 18.8% | -127.8% | ||
| Q3 25 | 0.3% | 0.7% | ||
| Q2 25 | 20.3% | -0.8% | ||
| Q1 25 | 13.4% | -0.6% | ||
| Q4 24 | 20.4% | -3.9% | ||
| Q3 24 | 22.6% | -1.9% | ||
| Q2 24 | 13.9% | -10.2% | ||
| Q1 24 | 9.5% | 0.2% |
| Q4 25 | $0.96 | $-10.23 | ||
| Q3 25 | $0.00 | $0.05 | ||
| Q2 25 | $0.87 | $-0.06 | ||
| Q1 25 | $0.35 | $-0.05 | ||
| Q4 24 | $0.56 | $-0.32 | ||
| Q3 24 | $1.63 | $-0.15 | ||
| Q2 24 | $0.40 | $-0.79 | ||
| Q1 24 | $0.18 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.1B | $2.9B |
| Total Assets | $29.1B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.2B | $432.1M | ||
| Q2 25 | $1.3B | $454.2M | ||
| Q1 25 | $1.2B | $409.9M | ||
| Q4 24 | $1.3B | $558.8M | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $914.8M | $542.8M | ||
| Q1 24 | $1.3B | $658.5M |
| Q4 25 | $7.1B | $2.9B | ||
| Q3 25 | $6.8B | $4.4B | ||
| Q2 25 | $6.7B | $4.5B | ||
| Q1 25 | $6.4B | $4.4B | ||
| Q4 24 | $6.3B | $4.3B | ||
| Q3 24 | $6.3B | $4.6B | ||
| Q2 24 | $5.7B | $4.5B | ||
| Q1 24 | $5.7B | $4.7B |
| Q4 25 | $29.1B | $8.5B | ||
| Q3 25 | $27.1B | $10.1B | ||
| Q2 25 | $25.1B | $10.1B | ||
| Q1 25 | $24.1B | $9.8B | ||
| Q4 24 | $23.1B | $9.6B | ||
| Q3 24 | $22.7B | $11.2B | ||
| Q2 24 | $22.3B | $10.4B | ||
| Q1 24 | $20.8B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.2B | $175.4M |
| Free Cash FlowOCF − Capex | $-1.2B | $148.6M |
| FCF MarginFCF / Revenue | -65.1% | 13.4% |
| Capex IntensityCapex / Revenue | 2.2% | 2.4% |
| Cash ConversionOCF / Net Profit | -3.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.4B | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.2B | $175.4M | ||
| Q3 25 | $-1.6B | $51.7M | ||
| Q2 25 | $-168.8M | $75.9M | ||
| Q1 25 | $-352.1M | $-64.5M | ||
| Q4 24 | $-352.8M | $312.6M | ||
| Q3 24 | $791.9M | $42.2M | ||
| Q2 24 | $-1.3B | $9.5M | ||
| Q1 24 | $71.1M | $-1.4M |
| Q4 25 | $-1.2B | $148.6M | ||
| Q3 25 | $-1.6B | $29.8M | ||
| Q2 25 | $-186.3M | $56.7M | ||
| Q1 25 | $-368.8M | $-90.0M | ||
| Q4 24 | $-379.5M | $274.9M | ||
| Q3 24 | $772.8M | $15.1M | ||
| Q2 24 | $-1.3B | $-18.9M | ||
| Q1 24 | $56.9M | $-26.5M |
| Q4 25 | -65.1% | 13.4% | ||
| Q3 25 | -475.7% | 2.9% | ||
| Q2 25 | -11.8% | 5.4% | ||
| Q1 25 | -37.9% | -8.6% | ||
| Q4 24 | -36.8% | 24.2% | ||
| Q3 24 | 29.3% | 1.4% | ||
| Q2 24 | -120.4% | -1.8% | ||
| Q1 24 | 8.3% | -2.4% |
| Q4 25 | 2.2% | 2.4% | ||
| Q3 25 | 7.0% | 2.1% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 2.6% | 3.3% | ||
| Q3 24 | 0.7% | 2.5% | ||
| Q2 24 | 1.7% | 2.7% | ||
| Q1 24 | 2.1% | 2.3% |
| Q4 25 | -3.34× | — | ||
| Q3 25 | -1732.78× | 6.89× | ||
| Q2 25 | -0.53× | — | ||
| Q1 25 | -2.71× | — | ||
| Q4 24 | -1.67× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | -8.57× | — | ||
| Q1 24 | 1.08× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CG
| Fund Management Fee | $606.8M | 32% |
| Other | $528.7M | 28% |
| Global Private Equity Segment | $307.3M | 16% |
| Global Credit Segment | $238.0M | 13% |
| Carlyle Alp Invest Segment | $124.6M | 7% |
| Incentive Fee | $55.4M | 3% |
| Fee Related Performance Revenues | $29.2M | 2% |
| Investment Advice | $11.1M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
